JP2004524294A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004524294A5 JP2004524294A5 JP2002557903A JP2002557903A JP2004524294A5 JP 2004524294 A5 JP2004524294 A5 JP 2004524294A5 JP 2002557903 A JP2002557903 A JP 2002557903A JP 2002557903 A JP2002557903 A JP 2002557903A JP 2004524294 A5 JP2004524294 A5 JP 2004524294A5
- Authority
- JP
- Japan
- Prior art keywords
- alpha
- mercaptopropyl
- carboxy
- compound
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 claims 18
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- -1 nitro, phenyl Chemical group 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 230000000694 effects Effects 0.000 claims 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 230000005856 abnormality Effects 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 7
- 208000012902 Nervous system disease Diseases 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 5
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229930195712 glutamate Natural products 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000017497 prostate disease Diseases 0.000 claims 4
- JKPYNGWTXQIZFC-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)benzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(C(O)=O)=C1 JKPYNGWTXQIZFC-UHFFFAOYSA-N 0.000 claims 3
- 238000009007 Diagnostic Kit Methods 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000001537 neural effect Effects 0.000 claims 3
- 210000002569 neuron Anatomy 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- MBRAISPPYRWIEP-UHFFFAOYSA-N 2-(1-carboxy-4-sulfanylbutoxy)benzoic acid Chemical compound SCCCC(C(=O)O)OC1=CC=CC=C1C(O)=O MBRAISPPYRWIEP-UHFFFAOYSA-N 0.000 claims 1
- AJRYUIBEXXWDCQ-UHFFFAOYSA-N 2-(2-carboxy-5-sulfanylpentyl)benzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC=C1C(O)=O AJRYUIBEXXWDCQ-UHFFFAOYSA-N 0.000 claims 1
- IPZDSCZXSXITRA-UHFFFAOYSA-N 2-(3,5-dimethoxyphenoxy)-5-sulfanylpentanoic acid Chemical compound COC1=CC(OC)=CC(OC(CCCS)C(O)=O)=C1 IPZDSCZXSXITRA-UHFFFAOYSA-N 0.000 claims 1
- SCEOWAMGFIJJCG-UHFFFAOYSA-N 2-(3-acetamidophenoxy)-5-sulfanylpentanoic acid Chemical compound CC(=O)NC1=CC=CC(OC(CCCS)C(O)=O)=C1 SCEOWAMGFIJJCG-UHFFFAOYSA-N 0.000 claims 1
- FNWKMVIZLRVPFM-UHFFFAOYSA-N 2-(3-acetylphenoxy)-5-sulfanylpentanoic acid Chemical compound CC(=O)C1=CC=CC(OC(CCCS)C(O)=O)=C1 FNWKMVIZLRVPFM-UHFFFAOYSA-N 0.000 claims 1
- NCNYBAYYAFRTGD-UHFFFAOYSA-N 2-(3-hydroxyphenoxy)-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)OC1=CC=CC(O)=C1 NCNYBAYYAFRTGD-UHFFFAOYSA-N 0.000 claims 1
- MAEHSMNJMWMSLR-UHFFFAOYSA-N 2-(4-acetylphenoxy)-5-sulfanylpentanoic acid Chemical compound CC(=O)C1=CC=C(OC(CCCS)C(O)=O)C=C1 MAEHSMNJMWMSLR-UHFFFAOYSA-N 0.000 claims 1
- BBCKAXJYWIDLIE-UHFFFAOYSA-N 2-(naphthalen-2-ylmethyl)-5-sulfanylpentanoic acid Chemical compound C1=CC=CC2=CC(CC(CCCS)C(=O)O)=CC=C21 BBCKAXJYWIDLIE-UHFFFAOYSA-N 0.000 claims 1
- VORQQRJSVLAQKA-UHFFFAOYSA-N 2-[(2,3,4,5,6-pentafluorophenyl)methyl]-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)CC1=C(F)C(F)=C(F)C(F)=C1F VORQQRJSVLAQKA-UHFFFAOYSA-N 0.000 claims 1
- VPXSPTBTKHLCQY-UHFFFAOYSA-N 2-[(2,5-dimethoxyphenyl)methyl]-5-sulfanylpentanoic acid Chemical compound COC1=CC=C(OC)C(CC(CCCS)C(O)=O)=C1 VPXSPTBTKHLCQY-UHFFFAOYSA-N 0.000 claims 1
- HCDFUWTYXMIYJA-UHFFFAOYSA-N 2-[(2-carbamoylphenyl)methyl]-5-sulfanylpentanoic acid Chemical compound NC(=O)C1=CC=CC=C1CC(CCCS)C(O)=O HCDFUWTYXMIYJA-UHFFFAOYSA-N 0.000 claims 1
- HGNBVXVFPLCFGS-UHFFFAOYSA-N 2-[(2-chlorophenyl)methyl]-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC=C1Cl HGNBVXVFPLCFGS-UHFFFAOYSA-N 0.000 claims 1
- PYQKBKPIINRFHX-UHFFFAOYSA-N 2-[(2-cyanophenyl)methyl]-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC=C1C#N PYQKBKPIINRFHX-UHFFFAOYSA-N 0.000 claims 1
- YGTHVCLIXDRTSW-UHFFFAOYSA-N 2-[(3-phenoxyphenyl)methyl]-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(OC=2C=CC=CC=2)=C1 YGTHVCLIXDRTSW-UHFFFAOYSA-N 0.000 claims 1
- KITPJWBAILLUCD-UHFFFAOYSA-N 2-[(3-phenylphenyl)methyl]-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(C=2C=CC=CC=2)=C1 KITPJWBAILLUCD-UHFFFAOYSA-N 0.000 claims 1
- JVYSQYAULLQAHP-UHFFFAOYSA-N 2-[(3-tert-butylphenyl)methyl]-5-sulfanylpentanoic acid Chemical compound CC(C)(C)C1=CC=CC(CC(CCCS)C(O)=O)=C1 JVYSQYAULLQAHP-UHFFFAOYSA-N 0.000 claims 1
- BGLKPRGXYUWMAQ-UHFFFAOYSA-N 2-[(4-acetamidophenyl)methyl]-5-sulfanylpentanoic acid Chemical compound CC(=O)NC1=CC=C(CC(CCCS)C(O)=O)C=C1 BGLKPRGXYUWMAQ-UHFFFAOYSA-N 0.000 claims 1
- URMIUKKJQBGPLB-UHFFFAOYSA-N 2-[(4-hydroxyphenyl)methyl]-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=C(O)C=C1 URMIUKKJQBGPLB-UHFFFAOYSA-N 0.000 claims 1
- QMOJKEADTCOMEJ-UHFFFAOYSA-N 2-[(4-methylsulfonylphenyl)methyl]-5-sulfanylpentanoic acid Chemical compound CS(=O)(=O)C1=CC=C(CC(CCCS)C(O)=O)C=C1 QMOJKEADTCOMEJ-UHFFFAOYSA-N 0.000 claims 1
- MIIIRKIXGXSNML-UHFFFAOYSA-N 2-[(4-phenylphenyl)methyl]-5-sulfanylpentanoic acid Chemical compound C1=CC(CC(CCCS)C(=O)O)=CC=C1C1=CC=CC=C1 MIIIRKIXGXSNML-UHFFFAOYSA-N 0.000 claims 1
- OWCSOMCOBIJMHW-UHFFFAOYSA-N 2-[3-(2-carboxy-5-sulfanylpentyl)phenoxy]benzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(OC=2C(=CC=CC=2)C(O)=O)=C1 OWCSOMCOBIJMHW-UHFFFAOYSA-N 0.000 claims 1
- WMNGUGVHZZFUSA-UHFFFAOYSA-N 2-[3-(2-carboxy-5-sulfanylpentyl)phenyl]benzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(C=2C(=CC=CC=2)C(O)=O)=C1 WMNGUGVHZZFUSA-UHFFFAOYSA-N 0.000 claims 1
- UIPBZNKBAOJQHA-UHFFFAOYSA-N 2-[3-(carboxymethyl)phenoxy]-5-sulfanylpentanoic acid Chemical compound OC(=O)CC1=CC=CC(OC(CCCS)C(O)=O)=C1 UIPBZNKBAOJQHA-UHFFFAOYSA-N 0.000 claims 1
- ZHWFQWFTXXLPSM-UHFFFAOYSA-N 2-[4-(2-carboxy-5-sulfanylpentyl)phenoxy]benzoic acid Chemical compound C1=CC(CC(CCCS)C(=O)O)=CC=C1OC1=CC=CC=C1C(O)=O ZHWFQWFTXXLPSM-UHFFFAOYSA-N 0.000 claims 1
- HYVADFIGJMMRLF-UHFFFAOYSA-N 2-[4-(carboxymethyl)phenoxy]-5-sulfanylpentanoic acid Chemical compound OC(=O)CC1=CC=C(OC(CCCS)C(O)=O)C=C1 HYVADFIGJMMRLF-UHFFFAOYSA-N 0.000 claims 1
- QKWJXRWWDNFRMK-UHFFFAOYSA-N 2-[[3-(benzylcarbamoyl)phenyl]methyl]-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(C(=O)NCC=2C=CC=CC=2)=C1 QKWJXRWWDNFRMK-UHFFFAOYSA-N 0.000 claims 1
- RSFRRAZDFPZZHT-UHFFFAOYSA-N 2-[[4-(2-cyanophenyl)phenyl]methyl]-5-sulfanylpentanoic acid Chemical compound C1=CC(CC(CCCS)C(=O)O)=CC=C1C1=CC=CC=C1C#N RSFRRAZDFPZZHT-UHFFFAOYSA-N 0.000 claims 1
- ULUAWVNJRKVRGR-UHFFFAOYSA-N 2-[[4-(carboxymethyl)phenyl]methyl]-5-sulfanylpentanoic acid Chemical compound OC(=O)CC1=CC=C(CC(CCCS)C(O)=O)C=C1 ULUAWVNJRKVRGR-UHFFFAOYSA-N 0.000 claims 1
- QTCRNIDSGWSKLN-UHFFFAOYSA-N 2-benzyl-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC=C1 QTCRNIDSGWSKLN-UHFFFAOYSA-N 0.000 claims 1
- WEFRBVOBYWNMNL-UHFFFAOYSA-N 2-bromo-4-(2-carboxy-5-sulfanylpentyl)benzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=C(C(O)=O)C(Br)=C1 WEFRBVOBYWNMNL-UHFFFAOYSA-N 0.000 claims 1
- NABZMSQIXDUMRM-UHFFFAOYSA-N 2-phenoxy-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)OC1=CC=CC=C1 NABZMSQIXDUMRM-UHFFFAOYSA-N 0.000 claims 1
- NGMNYTQZTGEAFW-UHFFFAOYSA-N 2-phenylsulfanyl-5-sulfanylpentanoic acid Chemical compound SCCCC(C(=O)O)SC1=CC=CC=C1 NGMNYTQZTGEAFW-UHFFFAOYSA-N 0.000 claims 1
- VVSWPNCZEUUAEH-UHFFFAOYSA-N 3-(1-carboxy-4-sulfanylbutoxy)-4-chlorobenzoic acid Chemical compound SCCCC(C(=O)O)OC1=CC(C(O)=O)=CC=C1Cl VVSWPNCZEUUAEH-UHFFFAOYSA-N 0.000 claims 1
- XCCFTWPWARLYSF-UHFFFAOYSA-N 3-(1-carboxy-4-sulfanylbutoxy)-4-fluorobenzoic acid Chemical compound SCCCC(C(=O)O)OC1=CC(C(O)=O)=CC=C1F XCCFTWPWARLYSF-UHFFFAOYSA-N 0.000 claims 1
- RMODAGPIACEGPS-UHFFFAOYSA-N 3-(1-carboxy-4-sulfanylbutoxy)-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC(CCCS)C(O)=O RMODAGPIACEGPS-UHFFFAOYSA-N 0.000 claims 1
- KUHQPVJMGPHXPD-UHFFFAOYSA-N 3-(1-carboxy-4-sulfanylbutoxy)benzoic acid Chemical compound SCCCC(C(=O)O)OC1=CC=CC(C(O)=O)=C1 KUHQPVJMGPHXPD-UHFFFAOYSA-N 0.000 claims 1
- YCOWYEFXMOFVIH-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylhexyl)benzoic acid Chemical compound CC(S)CCC(C(O)=O)CC1=CC=CC(C(O)=O)=C1 YCOWYEFXMOFVIH-UHFFFAOYSA-N 0.000 claims 1
- YQTWFQBGUQQUIS-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-2-chlorobenzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(C(O)=O)=C1Cl YQTWFQBGUQQUIS-UHFFFAOYSA-N 0.000 claims 1
- WYFGLPBEXWOGKD-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-2-phenylbenzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(C(O)=O)=C1C1=CC=CC=C1 WYFGLPBEXWOGKD-UHFFFAOYSA-N 0.000 claims 1
- YJZGGCGFCHKIDL-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-4-chlorobenzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC(C(O)=O)=CC=C1Cl YJZGGCGFCHKIDL-UHFFFAOYSA-N 0.000 claims 1
- YRXHZVLQYIPGME-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-4-fluorobenzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC(C(O)=O)=CC=C1F YRXHZVLQYIPGME-UHFFFAOYSA-N 0.000 claims 1
- YYJGYEDQOSRQAT-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1CC(CCCS)C(O)=O YYJGYEDQOSRQAT-UHFFFAOYSA-N 0.000 claims 1
- NKKCDHZUKWQWBD-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-4-nitrobenzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC(C(O)=O)=CC=C1[N+]([O-])=O NKKCDHZUKWQWBD-UHFFFAOYSA-N 0.000 claims 1
- FGXMYGFAXIKBMB-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-4-phenylbenzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC(C(O)=O)=CC=C1C1=CC=CC=C1 FGXMYGFAXIKBMB-UHFFFAOYSA-N 0.000 claims 1
- HQUGOWHIKUHTBD-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-5-methoxybenzoic acid Chemical compound COC1=CC(CC(CCCS)C(O)=O)=CC(C(O)=O)=C1 HQUGOWHIKUHTBD-UHFFFAOYSA-N 0.000 claims 1
- OGHVHZRXBBGIOP-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-5-nitrobenzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC(C(O)=O)=CC([N+]([O-])=O)=C1 OGHVHZRXBBGIOP-UHFFFAOYSA-N 0.000 claims 1
- NKZPFOFFSSROEI-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-5-phenoxybenzoic acid Chemical compound OC(=O)C1=CC(CC(CCCS)C(=O)O)=CC(OC=2C=CC=CC=2)=C1 NKZPFOFFSSROEI-UHFFFAOYSA-N 0.000 claims 1
- HTJJVJJZOQVJER-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-5-phenylbenzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC(C(O)=O)=CC(C=2C=CC=CC=2)=C1 HTJJVJJZOQVJER-UHFFFAOYSA-N 0.000 claims 1
- XHGGKLYPJOFAKF-UHFFFAOYSA-N 3-(2-carboxy-5-sulfanylpentyl)-5-phenylmethoxybenzoic acid Chemical compound OC(=O)C1=CC(CC(CCCS)C(=O)O)=CC(OCC=2C=CC=CC=2)=C1 XHGGKLYPJOFAKF-UHFFFAOYSA-N 0.000 claims 1
- LKVVCKVANGJUPA-UHFFFAOYSA-N 3-[3-(2-carboxy-5-sulfanylpentyl)phenyl]benzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(C=2C=C(C=CC=2)C(O)=O)=C1 LKVVCKVANGJUPA-UHFFFAOYSA-N 0.000 claims 1
- LLZCWFWIOCCIAQ-UHFFFAOYSA-N 3-bromo-5-(2-carboxy-5-sulfanylpentyl)benzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC(Br)=CC(C(O)=O)=C1 LLZCWFWIOCCIAQ-UHFFFAOYSA-N 0.000 claims 1
- LVHUJAJJDGLHQL-UHFFFAOYSA-N 3-tert-butyl-5-(1-carboxy-4-sulfanylbutoxy)benzoic acid Chemical compound CC(C)(C)C1=CC(OC(CCCS)C(O)=O)=CC(C(O)=O)=C1 LVHUJAJJDGLHQL-UHFFFAOYSA-N 0.000 claims 1
- GGVNQQHTCGBKLF-UHFFFAOYSA-N 3-tert-butyl-5-(1-carboxy-4-sulfanylbutyl)sulfanylbenzoic acid Chemical compound CC(C)(C)C1=CC(SC(CCCS)C(O)=O)=CC(C(O)=O)=C1 GGVNQQHTCGBKLF-UHFFFAOYSA-N 0.000 claims 1
- HKLMSSIZWZPLNJ-UHFFFAOYSA-N 3-tert-butyl-5-(2-carboxy-5-sulfanylhexyl)benzoic acid Chemical compound CC(S)CCC(C(O)=O)CC1=CC(C(O)=O)=CC(C(C)(C)C)=C1 HKLMSSIZWZPLNJ-UHFFFAOYSA-N 0.000 claims 1
- ZTTRAVPRWXCCDT-UHFFFAOYSA-N 3-tert-butyl-5-(2-carboxy-5-sulfanylpentyl)benzoic acid Chemical compound CC(C)(C)C1=CC(CC(CCCS)C(O)=O)=CC(C(O)=O)=C1 ZTTRAVPRWXCCDT-UHFFFAOYSA-N 0.000 claims 1
- RBOTZOZBOFRNAJ-UHFFFAOYSA-N 3-tert-butyl-5-[(1-carboxy-4-sulfanylbutyl)amino]benzoic acid Chemical compound CC(C)(C)C1=CC(NC(CCCS)C(O)=O)=CC(C(O)=O)=C1 RBOTZOZBOFRNAJ-UHFFFAOYSA-N 0.000 claims 1
- VSCKMEQIVKMGTJ-UHFFFAOYSA-N 4-(1-carboxy-4-sulfanylbutoxy)benzoic acid Chemical compound SCCCC(C(=O)O)OC1=CC=C(C(O)=O)C=C1 VSCKMEQIVKMGTJ-UHFFFAOYSA-N 0.000 claims 1
- REUAEBMGVYKKES-UHFFFAOYSA-N 4-(2-carboxy-5-sulfanylpentyl)-2,3,5,6-tetrafluorobenzoic acid Chemical compound SCCCC(C(=O)O)CC1=C(F)C(F)=C(C(O)=O)C(F)=C1F REUAEBMGVYKKES-UHFFFAOYSA-N 0.000 claims 1
- WDVWCNCIBNEXCG-UHFFFAOYSA-N 4-(2-carboxy-5-sulfanylpentyl)benzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=C(C(O)=O)C=C1 WDVWCNCIBNEXCG-UHFFFAOYSA-N 0.000 claims 1
- JNBOEQLMUREQEA-UHFFFAOYSA-N 4-(2-carboxy-5-sulfanylpentyl)naphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(CC(CCCS)C(=O)O)=CC=C(C(O)=O)C2=C1 JNBOEQLMUREQEA-UHFFFAOYSA-N 0.000 claims 1
- USWZTBGTFJZDLR-UHFFFAOYSA-N 4-bromo-3-(2-carboxy-5-sulfanylpentyl)benzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC(C(O)=O)=CC=C1Br USWZTBGTFJZDLR-UHFFFAOYSA-N 0.000 claims 1
- KSGZVOHKXDBHHY-UHFFFAOYSA-N 5-(2-carboxy-5-sulfanylpentyl)-2-chlorobenzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=C(Cl)C(C(O)=O)=C1 KSGZVOHKXDBHHY-UHFFFAOYSA-N 0.000 claims 1
- SGOHFUISINOJPA-UHFFFAOYSA-N 5-(2-carboxy-5-sulfanylpentyl)-2-fluorobenzoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=C(F)C(C(O)=O)=C1 SGOHFUISINOJPA-UHFFFAOYSA-N 0.000 claims 1
- CFVYQIURHMEAHF-UHFFFAOYSA-N 5-(2-carboxy-5-sulfanylpentyl)-2-phenylbenzoic acid Chemical compound OC(=O)C1=CC(CC(CCCS)C(=O)O)=CC=C1C1=CC=CC=C1 CFVYQIURHMEAHF-UHFFFAOYSA-N 0.000 claims 1
- RQTXPDQIDQNFKW-UHFFFAOYSA-N 5-(2-carboxy-5-sulfanylpentyl)benzene-1,3-dicarboxylic acid Chemical compound SCCCC(C(=O)O)CC1=CC(C(O)=O)=CC(C(O)=O)=C1 RQTXPDQIDQNFKW-UHFFFAOYSA-N 0.000 claims 1
- WDYYUVBQEGLHIH-UHFFFAOYSA-N 5-sulfanyl-2-[[3-(trifluoromethyl)phenyl]methyl]pentanoic acid Chemical compound SCCCC(C(=O)O)CC1=CC=CC(C(F)(F)F)=C1 WDYYUVBQEGLHIH-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010056677 Nerve degeneration Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 230000000893 fibroproliferative effect Effects 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000009689 neuronal regeneration Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26175401P | 2001-01-17 | 2001-01-17 | |
| US34277201P | 2001-12-28 | 2001-12-28 | |
| PCT/US2002/001205 WO2002057222A2 (en) | 2001-01-17 | 2002-01-17 | Thiol-based naaladase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008270033A Division JP2009051854A (ja) | 2001-01-17 | 2008-10-20 | チオールを含むｎａａｌａｄアーゼ抑制物質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004524294A JP2004524294A (ja) | 2004-08-12 |
| JP2004524294A5 true JP2004524294A5 (enExample) | 2005-12-22 |
| JP4234430B2 JP4234430B2 (ja) | 2009-03-04 |
Family
ID=26948812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002557903A Expired - Fee Related JP4234430B2 (ja) | 2001-01-17 | 2002-01-17 | チオールを含むｎａａｌａｄアーゼ抑制物質 |
| JP2008270033A Abandoned JP2009051854A (ja) | 2001-01-17 | 2008-10-20 | チオールを含むｎａａｌａｄアーゼ抑制物質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008270033A Abandoned JP2009051854A (ja) | 2001-01-17 | 2008-10-20 | チオールを含むｎａａｌａｄアーゼ抑制物質 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US6586623B2 (enExample) |
| EP (1) | EP1353903A2 (enExample) |
| JP (2) | JP4234430B2 (enExample) |
| AU (1) | AU2002245271B2 (enExample) |
| CA (1) | CA2435273A1 (enExample) |
| MX (1) | MXPA03006467A (enExample) |
| WO (1) | WO2002057222A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
| US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US7070782B1 (en) * | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| WO1996026272A1 (en) | 1995-02-24 | 1996-08-29 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| US6569432B1 (en) * | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| US20040253246A1 (en) * | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
| MXPA03006467A (es) * | 2001-01-17 | 2004-01-29 | Guilford Pharm Inc | Inibidores de naaladasa a base de tiol. |
| CA2436408A1 (en) | 2001-02-07 | 2002-12-12 | Beth Israel Deaconess Medical Center | Modified psma ligands and uses related thereto |
| US7148250B2 (en) * | 2001-12-28 | 2006-12-12 | Guilford Pharmaceuticals Inc. | Indoles as NAALADase inhibitors |
| DE602004021476D1 (de) * | 2003-03-03 | 2009-07-23 | Eisai Corp North America | THIOLACTONE ALS NAALADase INHIBITOREN |
| US20040186081A1 (en) * | 2003-03-03 | 2004-09-23 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating opioid tolerance |
| JP2008505884A (ja) | 2004-07-08 | 2008-02-28 | エヌエスティー・ニューロサバイバル・テクノロジーズ・リミテッド | 疾患を検出する方法および化合物 |
| US8023934B2 (en) * | 2008-03-28 | 2011-09-20 | Ianywhere Solutions, Inc. | Synchronizing communications and data between mobile devices and servers |
| US8019863B2 (en) | 2008-03-28 | 2011-09-13 | Ianywhere Solutions, Inc. | Synchronizing events between mobile devices and servers |
| US20110093619A1 (en) * | 2009-10-16 | 2011-04-21 | Ianywhere Solutions, Inc. | Synchronizing Tasks between Mobile Devices and Servers |
| US8434097B2 (en) * | 2009-12-30 | 2013-04-30 | Sybase, Inc. | Dynamic data binding for MBOs for container based application |
| KR102722949B1 (ko) * | 2015-06-15 | 2024-10-28 | 엔엠디 파마 에이/에스 | 신경근 장애의 치료에 사용하기 위한 화합물 |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0994707A4 (en) * | 1997-05-27 | 2001-11-14 | Guilford Pharm Inc | INHIBITORS OF NAALADASE ENZYME ACTIVITY |
| MXPA01000144A (es) * | 1998-07-06 | 2002-10-17 | Guilford Pharm Inc | Inhibidores de naaladasa utiles como composiciones y compuestos farmaceuticos. |
| US20020013295A1 (en) | 2000-05-30 | 2002-01-31 | Slusher Barbara S. | Naaladase inhibitors for treating amyotrophic lateral sclerosis |
| WO2001092274A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating retinal disorders and glaucoma |
| AU2001265111A1 (en) * | 2000-05-30 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
| MXPA03006467A (es) * | 2001-01-17 | 2004-01-29 | Guilford Pharm Inc | Inibidores de naaladasa a base de tiol. |
-
2002
- 2002-01-17 MX MXPA03006467A patent/MXPA03006467A/es active IP Right Grant
- 2002-01-17 CA CA002435273A patent/CA2435273A1/en not_active Abandoned
- 2002-01-17 WO PCT/US2002/001205 patent/WO2002057222A2/en not_active Ceased
- 2002-01-17 JP JP2002557903A patent/JP4234430B2/ja not_active Expired - Fee Related
- 2002-01-17 EP EP02713419A patent/EP1353903A2/en not_active Withdrawn
- 2002-01-17 AU AU2002245271A patent/AU2002245271B2/en not_active Ceased
- 2002-01-17 US US10/046,917 patent/US6586623B2/en not_active Expired - Fee Related
-
2003
- 2003-05-08 US US10/431,462 patent/US6812364B2/en not_active Expired - Fee Related
-
2004
- 2004-10-07 US US10/959,199 patent/US6992215B2/en not_active Expired - Fee Related
-
2006
- 2006-01-05 US US11/325,602 patent/US20060135812A1/en not_active Abandoned
-
2008
- 2008-10-20 JP JP2008270033A patent/JP2009051854A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60315603T2 (de) | Modulatoren von peroxisome proliferator-aktivierten rezeptoren | |
| JP2657583B2 (ja) | 神経系変性疾患の治療に対するニコチン類似体の利用 | |
| DE69826286T2 (de) | Derivate mit einem aromatischen ring | |
| DE69916881T2 (de) | Antihypertriglyceridemische, antihyperglykemische, antiangiogene und wundheilende substituierte indolalkansäure | |
| DE69124798T2 (de) | 3-aryl-2-hydroxypropionsäurederivate und analoge als hypoglykämische mittel | |
| KR101342547B1 (ko) | 망막 질환을 치료하기 위한 조성물 및 방법 | |
| US10618893B2 (en) | GPR120 agonists for the treatment of type II diabetes | |
| US7148250B2 (en) | Indoles as NAALADase inhibitors | |
| JP2000509395A (ja) | 無機イオン活性化合物 | |
| JP2009051854A (ja) | チオールを含むｎａａｌａｄアーゼ抑制物質 | |
| CN1210531A (zh) | 用作抗炎剂的二氢苯并呋喃和相关化合物 | |
| JPH0141629B2 (enExample) | ||
| JP2013512243A (ja) | 治療的有用性を有する受容体調節物質としての新規化合物 | |
| JP2005503353A5 (enExample) | ||
| JP2001523716A (ja) | 神経変性を防ぎ、そして神経再生を促進するための置換されたアミノメチルクロマンの利用 | |
| DE60316780T2 (de) | Modulatoren von peroxisome proliferator-aktivierten rezeptoren | |
| US7220780B2 (en) | Naaladase inhibitors for treating retinal disorders and glaucoma | |
| CA2448089A1 (en) | Thiolalkyl benzoic acid derivatives | |
| NZ204177A (en) | Phenethanolamine derivatives and pharmaceutical compositions | |
| EP0345068B1 (en) | Agonist of gamma-aminobutyric acid | |
| EP1086682B1 (en) | Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of neurogenic inflammation | |
| US12234208B2 (en) | 3,4-dihydroxy-n-(1′-benzyl-2′-hydroxyethyl)-2-methylpyridine chloride, and synthesis and use thereof | |
| WO2024263563A1 (en) | Metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators and uses thereof | |
| JP2005538126A (ja) | 耳鳴の処置のためのカルボキサミドの使用 | |
| JP4010377B2 (ja) | Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |